Marginal zone lymphoma+1
Not recruitingStudy Comparing Zanubrutinib, Obinutuzumab, and Rituximab with Lenalidomide and Rituximab for Patients with Relapsed or Refractory Follicular or Marginal Zone Lymphoma
Study Comparing Zanubrutinib, Obinutuzumab, and Rituximab with Lenalidomide and Rituximab for Patients with Relapsed or Refractory Follicular or Marginal Zone Lymphoma
- Disease:Marginal zone lymphomaFollicle centre lymphoma follicular grade I, II - III
- Substances:LenalidomideObinutuzumab+2
Italy- Participants:18–64 years · 65+ years
- Substances:Lenalidomide
- Sponsor:BeOne Medicines AG













